Image credit: https://www.boehringer-ingelheim.com
Boehringer Ingelheim has received approval from the Central Drugs Standard Control Organisation (CDSCO) to market its innovator drug Jardiance (empagliflozin) in India, for the treatment of heart failure with preserved ejection fraction (HFpEF).
With this approval, Jardiance is now the first and only clinically approved therapy to reduce the risk of cardiovascular death plus hospitalisation for heart failure in adults with heart failure, across the full spectrum of ejection fraction.
The new indication approval applies to eligible patients with HFpEF, regardless of their type-2 diabetes status, and is an addition to the previously approved indications for glycemia control in type-2 diabetes, as well as for reducing the risk of cardiovascular death plus hospitalization for adults with heart failure with reduced ejection fraction (HFrEF).
